Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Status:
Recruiting
Trial end date:
2026-07-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of belzutifan in
combination with pembrolizumab and lenvatinib in multiple solid tumors including
hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma
(PDAC), and biliary tract cancer (BTC). There is no formal hypothesis testing in this study.